1. Experimental modeling systems have utility in identifying biomarkers as long as the assumptions and limitations of the system are realized and the model endpoints are predictive of the clinical outcome. 2. The use of molecular profiling for compound ranking is possible, but this ranking may be more useful to verify a modeling system which can then be used to identify potential pre-clinical or clinical biomarkers. 3. Technological advancements in proteomic profiling and data mining will greatly facilitate its use in biomarker identification.
展开▼
